Form 4: Insmed CMO Executes Planned Stock Sale

Insmed Chief Medical Officer Martina Flammer sold 4,424 shares of common stock to cover tax obligations and via a 10b5-1 plan.

Summary

• Chief Medical Officer Martina Flammer sold a total of 4,424 shares of Insmed Inc (INSM) common stock.
• The transactions occurred on June 3, 2026, and June 5, 2026.
• 2,566 shares were sold at $102.27 per share to satisfy tax withholding obligations.
• 1,858 shares were sold at $103.78 per share pursuant to a pre-established 10b5-1 trading plan.
• Following these transactions, the reporting person retains 60,486 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were primarily driven by tax obligations and a pre-existing 10b5-1 plan rather than a change in outlook.

Positives

• The sale of 1,858 shares was conducted under a pre-arranged 10b5-1 trading plan, indicating a systematic approach to liquidity rather than a reactive market decision.

Negatives

• The reduction in direct equity ownership by a key executive may be viewed as a decrease in personal stake alignment.

Risks

• Continued reliance on 10b5-1 plans for executive liquidity can lead to periodic selling pressure on the stock.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling for tax obligations and via 10b5-1 plans is standard practice in the biotechnology sector, where equity-based compensation is a significant component of executive pay packages.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard governance practice among S&P 500 and mid-cap biotech firms to avoid allegations of insider trading.
• The sale volume represents a small fraction of the executive's total holdings, which is consistent with typical executive portfolio rebalancing.

Stakeholder Impact

• Minimal impact expected as the sales were executed through pre-planned mechanisms.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Insmed, INSM, Insider Trading, Form 4, Biotech, Executive Compensation